ClinicalTrials.gg
CompletedNCT07018388Updated Nov 18, 2026

Intrapatient Comparison of STN and GPi tTIS in PD

An interventional study of Transcranial temporal interference stimulation and Transcranial temporal interference stimulation in Parkinson Disease, sponsored by Ruijin Hospital. Completed at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Parkinson Disease by Ruijin Hospital — 8 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · Ruijin Hospital.

Enrollment
9th of 18
30 · median 29
Started
2025
with 4 others
No phase
16 of 20
5 open now
Registered
14th of 20
by date

Among the 20 studies in Parkinson Disease by Ruijin Hospital, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, and was the 14th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

8 of the 20 studies in Parkinson Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Parkinson Disease by Ruijin Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the therapeutic efficacy of tTIS in patients with Parkinson's disease and to evaluate the immediate effects and conduct intrapatient comparisons of individualized 130 Hz Subthalamic Nucleus-transcranial Temporal Interference Stimulation (STN-tTIS) and Globus Pallidus Internus-transcranial Temporal Interference Stimulation (GPi-tTIS) on motor symptoms in patients with early to mid-stage Parkinson's Disease (PD) during "off" medication states.

The main questions this study aims to answer are:

  1. Can tTIS significantly improve the motor symptoms of patients with Parkinson's disease?
  2. Is the therapeutic effect of STN-tTIS superior to that of GPi-tTIS?
Read the detailed description

This clinical trial aims to verify the efficacy of tTIS in patients with Parkinson's disease and to explore which targets are better for improving PD motor symptoms.Patients were randomly assigned to receive Stimulation Type A, B, or C. Type A received STN-tTIS therapy; Type B received GPi-tTIS therapy; Type C received sham stimulation targeting the subthalamic nucleus.

Each session lasted 20 minutes, and patients were in the off-medication state for all treatments.The order of stimulation types was randomized, with at least 7 days of washout between sessions to avoid carryover effects. MDS-UPDRS-III evaluations were assessed before and after each treatment.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • subthalamic nucleus
  • Globus Pallidus Internus
  • transcranial temporal interference stimulation
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary Parkinson's disease (MDS);
  • Hoehn \& Yahr stage ≤ 3;
  • Antiparkinsonian drugs must have remained unchanged in the past four weeks, and the dosage must have remained stable throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of neurological disorders that may affect the study (e.g., traumatic brain injury);
  • Antipsychotics, antidepressants, or dopamine modulators outside of PD drugs;
  • Metal devices in the head or heart (e.g., deep brain stimulators, pacemakers);
  • Unstable vital signs.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    STN-tTIS

    Patients in this group receive 20 minutes of individualized 130 Hz STN-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ before and after treatment.

    Device: Transcranial temporal interference stimulation

  • Experimental
    GPi-tTIS

    Patients in this group receive 20 minutes of individualized 130 Hz GPi-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ both before and after treatment.

    Device: Transcranial temporal interference stimulation

  • Experimental
    Sham stimulation

    Patients in this group receive sham stimulation targeting the subthalamic nucleus in the more affected hemisphere during the medication "off" state. Sham uses each participant's own STN-tTIS montage, with both channels delivering 2000 Hz so that the stimulation beat frequency is 0 Hz and no interference envelope is produced. Current is ramped up over 30 seconds and back to 0 mA over the next 30 seconds, with no stimulation for the remainder of the session. Each session lasts 20 minutes, and the MDS-UPDRS-III is assessed both before and after treatment.

    Device: Transcranial temporal interference stimulation

Interventions

  • DeviceTranscranial temporal interference stimulation

    To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling.

  • DeviceTranscranial temporal interference stimulation

    To design the individualized GPi-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data is used to determine the GPi-tTIS montage and stimulation settings via computational modeling.

  • DeviceTranscranial temporal interference stimulation

    To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling. Sham stimulation replicated this montage without producing an interference envelope.

06

What researchers measure

Primary outcomes

  1. MDS-UPDRS-Ⅲ scores

    The score range for MDS-UPDRS-III is from 0 to 132. The minimum value is 0, indicating no motor impairment, and the maximum value is 132, indicating the most severe motor impairment. Higher scores on the MDS-UPDRS-III indicate worse outcomes, as they reflect greater severity of motor symptoms.

    Time frame: pre-intervention, immediately after the intervention

Secondary outcomes

  1. MDS-UPDRS-Ⅲ sub-scores

    The MDS-UPDRS-III assesses motor symptoms in Parkinson's disease through sub-scores: Tremor Sub-score: Items 3.15-3.18; range 0-16. Higher scores indicate more severe tremors. Rigidity Sub-score: Item 3.3 (neck and four limbs); range 0-20. Higher scores reflect greater rigidity. Bradykinesia Sub-score: Items 3.2, 3.4-3.8, and 3.14; range 0-28. Higher scores indicate more severe slowness of movement. Axial Sub-score: Items 3.1 and 3.9-3.13; range 0-24. Higher scores suggest more significant axial impairments.

    Time frame: pre-intervention, immediately after the intervention

  2. Number of participants with adverse events

    Adverse events were assessed by volunteered report and categorized by preferred term and severity (mild, moderate, severe). The number of participants experiencing at least one adverse event was summarized for each stimulation condition in the safety population (all participants exposed to any condition). Serious adverse events were summarized separately.

    Time frame: During each 20-minute intervention session and through the post-intervention assessment on the same day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 7 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Apr 2025 → Aug 2025, primary completion Nov 2026 → Apr 2026 and completion Nov 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 12, 2025
StartActual
Aug 25, 2025was Apr 2025
Primary completionActual
Apr 10, 2026was Nov 2026
CompletionActual
Apr 10, 2026was Nov 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 18, 2026
Start date
Apr 23, 2025→Aug 25, 2025
Nov 18, 2026
Primary completion
Nov 1, 2026→Apr 10, 2026 (actual)
Nov 18, 2026
Study completion
Nov 1, 2026→Apr 10, 2026 (actual)
Nov 18, 2026
Enrollment
100 (estimated)→30 (actual)
Nov 18, 2026
Interventions
Changed NervioX-2400→Transcranial temporal interference stimulation. Added Device: Transcranial temporal interference stimulation; removed Device: NervioX-2400
Nov 18, 2026
Secondary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedNumber of participants with adverse eventsTime frame: During each 20-minute intervention session and through the post-intervention assessment on the same day
  • DescriptionMDS-UPDRS-Ⅲ sub-scores: how it is measured was reworded
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Enrolling by invitation→Completed
    Start date Apr 23, 2025→Aug 25, 2025
    Primary completion Nov 1, 2026→Apr 10, 2026 (now actual)
    Study completion Nov 1, 2026→Apr 10, 2026 (now actual)
    Enrollment 100 (estimated)→30 (actual)
    Secondary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedNumber of participants with adverse eventsTime frame: During each 20-minute intervention session and through the post-intervention assessment on the same day
    • DescriptionMDS-UPDRS-Ⅲ sub-scores: how it is measured was reworded
    Interventions Changed NervioX-2400→Transcranial temporal interference stimulation. Added Device: Transcranial temporal interference stimulation; removed Device: NervioX-2400
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07018388
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Aug 25, 2025
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion